Email Sign-Up
 
56 results found
Filter Filters icon
Apply

Story 06/05/23

Reducing ovarian function yields better outcomes for young women with breast cancer

A review of multiple studies shows benefit of ovarian function suppression or ablation for young women with early-stage, estrogen receptor-positive breast cancer or who were at risk of breast ...

Story 04/21/23

Beyond the headlines: Finances and disparities in breast cancer

Our April column focuses on financial toxicity, disparities in care for older adults and Black women, ribociclib in early-stage breast cancer, and more.

Story 04/13/23

Balancing a career and breast cancer: Tiffany’s story

In episode 3 of LBBC’s new Can and Did podcast, Tiffany shares how she shifted her perspective on health and work after a breast cancer diagnosis.

Article

Elacestrant

Elacestrant (Orserdu) is a hormonal therapy used to treat metastatic breast cancer.

Article

Ribociclib

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Article

Palbociclib

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Article

Abemaciclib

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Article

Targeted therapy for hormone receptor-positive breast cancer

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal ...

Story 12/13/22

New breast cancer drug targets AKT pathway

Capivasertib on track for possible FDA approval in metastatic hormone receptor-positive disease

Story 12/09/22

Elacestrant on course to gain FDA approval

Elacestrant is poised to move forward as a new option for metastatic hormone receptor-positive, HER2-negative  breast cancer in 2023. New results point to a relationship between the drug’s ...